Benefits and Risks of Transplantation: The Changing Therapeutic Paradigm for Multiple Myeloma: A Conversation With Paul G. Richardson, MD

Although high-dose chemotherapy plus autologous transplantation has been a standard of care in the treatment of younger patients with newly diagnosed multiple myeloma, the advent of effective novel agents for the cancer over the past 15 years has raised the question of whether transplantation, with its myriad toxicities, is still necessary.

 The ASCO Post

By continuing to browse this site you permit us and our partners to place identification cookies on your browser and agree to our use of cookies to identify you for marketing. Read our Privacy Policy to learn more.